MAR MAR 1997 AT MADEMARY

Docket No. 2026-4124

PATENT

UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Kawakami et al.

Group Art Unit: 1806

Serial No.

08/231,565

Examiner: S. Huff

15/C Cswett 4/18/97

Filed

April 22, 1994

For

MELANOMA ANTIGENS AND THEIR USE IN DIAGNOSTIC

AND THERAPEUTIC METHODS

Assistant Commissioner for Patents Washington, D.C. 20231

RECEIVED

APR 1 1 1997

AMENDMENT AND RESPONSE

GRUUT IL.

Sir:

This is in response to the Office Action dated September 19, 1995. Applicants have petitioned concurrently herewith to extend the period to respond to that Office Action for three (3) months up to and including March 19, 1996 and have said the appropriate fee under 37 C.F.R. §1.136 and 1.117. Please amend the application as follows:

IN THE CLAIMS

Please cancel claims 1-5 without prejudice or disclaimer.

Please amend the claims as follows:

56. (Amended) A purified and isolated nucleic acid sequence encoding a

270 LC 13-4500 04709/97 08231565

29033 102 160.00CH

peptide, said peptide comprising at least about 8 contiguous samino acids [-said open tide=being]

derived from the MART-1 (melanoma antigen recognized by T-cells-1) amino acid sequence

285095_1

EH910041021US